Forging Pathways for Rare Disease Access at World Orphan Drug Congress 2026

The World Orphan Drug Congress USA 2026 convenes on June 9 at the Thomas M. Menino Convention & Exhibition Center in Boston to examine practical strategies that advance orphan drug development and rare disease access. The day centers on interactive workshops that address policy barriers, regulatory processes, global pricing dynamics, mental health support, investment criteria, translational research, and launch planning. Organizers aim to equip participants with actionable insights that strengthen advocacy, align development decisions with access realities, and foster collaboration across patient groups, regulators, and industry.

Navigating Policy, Regulation, and Global Market Pressures

Morning sessions open with an examination of health insurance coverage policies that affect rare disease therapies throughout the product life cycle, emphasizing sustained advocacy from discovery through commercialization. Participants explore how patient perspectives can shape trial design and payer policies, supported by examples from the Immune Deficiency Foundation. Subsequent workshops turn to regulatory agility, sharing outcomes from initiatives that balance evidentiary standards with flexibility in rare disease treatment development, and to Most Favoured Nation and International Reference Pricing implications for European launch sequencing and early access models. Afternoon workshops extend these themes by analyzing CMS and administration policies, the potential emergence of health technology assessment in the United States, and the need for patient assistance programs to adapt amid growing competition. Parallel discussions address translational science tools, including AAV gene therapy platforms and stem-cell-derived 3D models, that move promising assets from preclinical stages toward clinical application.

Voices Guiding Patient-Centered and Investment Strategies

Prominent contributors include Stephanie Steele and Eric Feigen of the Immune Deficiency Foundation, who detail payer relations and regulatory advocacy; Jennifer McNary of Canary Concierge, moderating regulatory agility outcomes alongside Susan Winckler of the Reagan Udall Foundation for the FDA; and Andrew Cummins of Sciensus Pharma Services Limited, leading interactive exercises on global pricing risks. Mental health programming features Albert Freedman of Rarecounseling.com and Julie Wells of Give an Hour, while investment workshops draw Chris Garabedian of Perceptive Advisors, Laura Tadvalkar of RA Capital Management, and Mary Schaheen of Prevail Partners LLC.

Ad

Additional perspectives come from Amanda Forys, Amanda O’Hara, and Tracy Baroni Allmon of Magnolia Market Access on policy responses; Richa Madan Lomash and Elizabeth Ottinger of NIH/NCATS on translational resources; Sonit Handa of Biovance Consulting on early global launch design; and Melody Kisor of the FamilieSCN2A Foundation alongside Erica Barnes of the Minnesota Rare Disease Advisory Council on FDA engagement pathways for patient advocacy groups. These speakers collectively represent payer policy, regulatory affairs, market access consulting, venture capital, government research, and patient advocacy organizations.

Implications for Coordinated Rare Disease Advancement

The June 9 workshops collectively underscore how early integration of patient input, pricing considerations, and regulatory engagement can reduce downstream barriers to therapy availability. Discussions on mental health support and FDA pathways illustrate mechanisms for embedding community experience into development priorities, while sessions on venture criteria and translational platforms highlight factors that influence which assets attract funding and progress toward the clinic. By linking policy shifts, global access constraints, and operational flexibility, the agenda points toward more deliberate sequencing of development and commercialization decisions that preserve options across markets. These exchanges establish a foundation for subsequent congress days by clarifying shared challenges that span advocacy, investment, and regulatory domains.